Established vascular risk factors (ie, smoking, hypertension, diabetes mellitus, and dyslipidemia) play an important role in the development of vascular disease. Emerging evidence suggests that some of these risk factors may have a more intense effect on specific arterial beds, a finding that holds implications for a prognostic role for certain types of vascular disease.
Sritara P., Sritara C., Woodward M., et al. Prevalence and risk factors of peripheral arterial disease in a selected Thai population. Angiology. 2007 ;58:572-578.
2.
Paraskevas KI , Mikhailidis DP, Liapis CDInternal carotid artery occlusion: association with atherosclerotic disease in other arterial beds and vascular risk factors . Angiology. 2007;58:329-335.
3.
Mikhailidis DP, Press M.The importance of treating multiple cardiometabolic risk factors in patients with type 2 diabetes. Expert Opin Pharmacother. 2007;8:3009-3020.
4.
Tziomalos K. , Weerasinghe CN, Mikhailidis DP, Seifalian AMVascular risk factors in South Asians [published online ahead of print February 4, 2008]. Int J Cardiol. doi: 10.1016/j.ijcard.2007.11.059.
5.
Kakafika AI, Liberopoulos EN, Karagiannis A., Athyros VG, Mikhailidis DPDyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol. 2006;4:175-183.
6.
Fatourou EM, Paraskevas KI, Seifalian AM, Hamilton G., Mikhailidis DPThe role of established and emerging risk factors in peripheral vascular graft occlusion. Expert Opin Pharmacother. 2007;8:901-911.
7.
Paraskevas KI , Hamilton G., Cross JM, Mikhailidis DPAtherosclerotic renal artery stenosis: association with emerging vascular risk factors. Nephron Clin Pract. 2008;108:c56-c66.
8.
Daskalopoulou SS, Pathmarajah M., Kakkos SK, et al. Association between ankle -brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. Circ J. 2008;72:441-448.
9.
Paraskevas KI , Mikhailidis DPC-reactive protein (CRP): more than just an innocent bystander? Curr Med Res Opin. 2008 ;24:75-78.
10.
Jatoi NA, Jerrard-Dunne P., Feely J., Mahmud A.Impact of smoking and smoking cessation on arterial stiffness and aortic wave reflection in hypertension. Hypertension. 2007;49:981-985.
11.
Athyros VG, Liberopoulos EN, Mikhailidis DP, et al. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. Angiology. 2007;58:689-697.
12.
Kakafika AI , Mikhailidis DPSmoking and aortic diseases. Circ J. 2007;71:1173-1180.
13.
Rempher KJCardiovascular sequelae of tobacco smoking. Crit Care Nurs Clin North Am. 2006;18:13-20.
14.
McBride PEThe health consequences of smoking. Cardiovascular diseases. Med Clin North Am.1992;76: 333-353.
15.
Tonstad S., Andrew JJCardiovascular risks associated with smoking: a review for clinicians. Eur J Cardiovasc Prev Rehabil. 2006;13:507-514.
16.
Takagi H., Umemoto T.Smoking promotes pathogenesis of aortic aneurysm through the 5-lipoxygenase pathway. Med Hypotheses. 2005;64:1117-1119.
17.
Csonka E., Somogyi A., Augustin J., Haberbosch W., Schettler G., Jellinek H.The effect of nicotine on cultured cells of vascular origin. Virchows Arch A Pathol Anat Histopathol. 1985;407:441-447.
18.
Rahman MM, Laher I.Structural and functional alteration of blood vessels caused by cigarette smoking: an overview of molecular mechanisms. Curr Vasc Pharmacol . 2007;5:276-292.
19.
Tsiara S., Elisaf M., Mikhailidis DPInfluence of smoking on predictors of vascular disease. Angiology . 2003;54:59-71.
20.
Naya T., Hosomi N., Oyama H., et al. Smoking, fasting serum insulin and obesity are the predictors of carotid atherosclerosis in relatively young subjects. Angiology. 2007;58:625-629.
21.
Karakaya O. , Barutcu I., Kaya D., et al. Acute effect of cigarette smoking on heart rate variability. Angiology. 2007 ;58:620-624.
22.
Giannini D. , Leone A., Di Bisceglie D., et al. The effects of acute passive smoke exposure on endothelium-dependent brachial artery dilation in healthy individuals . Angiology. 2007;58:211-217.
23.
Oren S., Isakov I., Golzman B., et al. The influence of smoking cessation on hemodynamics and arterial compliance. Angiology. 2006;57:564-568.
24.
Cui R., Iso H., Yamagishi K., et al. Relationship of smoking and smoking cessation with ankle-to-arm blood pressure index in elderly Japanese men. Eur J Cardiovasc Prev Rehabil. 2006;13:243-248.
25.
Benowitz NLCigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis. 2003;46:91-111.
26.
Sobel BE, Schneider DJCardiovascular complications in diabetes mellitus. Curr Opin Pharmacol. 2005;5:143-148.
27.
Marso SP, Hiatt WRPeripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47: 921-929.
28.
Srikanth S., Deedwania P.Management of coronary artery disease in patients with type 2 diabetes mellitus . Curr Cardiol Rep. 2007;9:264-271.
29.
Air EL, Kissela BMDiabetes, the metabolic syndrome, and ischemic stroke: epidemiology and possible mechanisms. Diabetes Care. 2007;30:3131-3140.
30.
LaMorte WW, Scott TE, Menzoian JORacial differences in the incidence of femoral bypass and abdominal aortic aneurysmectomy in Massachusetts: relationship to cardiovascular risk factors . J Vasc Surg. 1995;21:422-431.
31.
Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs' Cooperative Study Group. Ann Intern Med.1997 ;126:441-449.
32.
Lederle FA, Johnson GR, Wilson SE, et al. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med.2000;160:1425-1430.
33.
Le MT, Jamrozik K., Davis TM, Norman PENegative association between infra-renal aortic diameter and glycaemia: the health in men study. Eur J Vasc Endovasc Surg. 2007;33:599-604.
Norman PE, Davis TM, Le MT, et al. Matrix biology of abdominal aortic aneurysms in diabetes: mechanisms underlying the negative association. Connect Tissue Res. 2007;48:125-131.
36.
Alnaeb ME, Thompson CS, Seifalian AM, Hamilton G., Mikhailidis DPRegional differences in the expression of nitric oxide synthase and specific receptors in the vascular tissues of control and diabetic rabbits: a pilot study. In Vivo. 2007;21:1069-1074.
37.
Rossing P.The changing epidemiology of diabetic microangiopathy in type I diabetes. Diabetologia. 2005;48:1439-1444.
38.
Jawa A., Kcomt J., Fonseca VADiabetic nephropathy and retinopathy. Med Clin North Am. 2004;88:1001-1036.
39.
Cordonnier C., Al-Shahi Salman R., Wardlaw J.Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain. 2007;130:1988-2003.
40.
Jamieson DGSecondary prevention of ischemic stroke: evolution from a stepwise to a risk stratification approach to care. Dis Manag. 2007;10:273-284.
41.
Tacoy G., Balcioglu AS, Akinci S., et al. Traditional risk factors are predictive on segmental localization of coronary artery disease. Angiology. In press. 2008;
42.
Nichols GA, Nag S., Chan W.Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the2004National Cholesterol Education Program Adult Treatment Panel III update. Am Heart J. 2007;154:554-560.
43.
Spratt KAReducing the risk of coronary heart disease via lipid reduction. J Am Osteopath Assoc. 2004;104:S9-S13.
44.
Daskalopoulou SS, Daskalopoulos ME, Liapis CD, Mikhailidis DPPeripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem. 2005;12:443-452.
45.
Alnaeb ME, Alobaid N., Seifalian AM, Mikhailidis DP, Hamilton G.Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg. 2006;20:696-705.
46.
Youssef F., Gupta S., Seifalian AM, Myint F., Mikhailidis DP, Hamilton G.The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology. 2004;55:53-62.
47.
Davis M., Atwal AS, Nair DR, et al. The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study. Curr Med Res Opin. 2000;16:198-204.
48.
Khan S., Flather M., Mister R., et al. Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry . Eur J Vasc Endovasc Surg. 2007;33:442-450.
49.
Bianchi C., Montalvo V., Ou HW, Bishop V., Abou-Zamzam AM Jr.Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann Vasc Surg . 2007;21:163-166.
50.
Al-Omran M.Knowledge and attitude of physicians in a major teaching hospital towards atherosclerotic risk reduction therapy in patients with peripheral arterial disease. Vasc Health Risk Manag. 2007;3:1019-1027.
51.
Goldstein LB , Amarenco P., Szarek M., et al; on behalf of the SPARCL Investigators.Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels [published online ahead of print December 12, 2007]. Neurology. Neurology. doi: 10.1212/01.wnl.0000296277 .63350.77.
52.
Sinha AK, Misra GC, Patel DKEffect of cigarette smoking on lipid profile in the young. J Assoc Physicians India. 1995;43:185-188.
53.
Venkatesan A., Hemalatha A., Bobby Z., Selvaraj N., Sathiyapriya V.Effect of smoking on lipid profile and lipid peroxidation in normal subjects. Indian J Physiol Pharmacol . 2006;50:273-278.
54.
O'Loughlin J. , Lambert M., Karp I., et al. Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents . Nicotine Tob Res. 2008;10:525-532.
55.
Kakafika AI, Liberopoulos EN, Mikhailidis DPFibrinogen: a predictor of vascular disease. Curr Pharm Des . 2007;13:1647-1659.
56.
Bartsocas CS, Gerasimidi-Vazeou A.Genetics of type I diabetes mellitus. Pediatr Endocrinol Rev . 2006;3:508-513.
57.
Nejentsev S. , Howson JM, Walker NM, et al; Wellcome Trust Case Control Consortium.Localization of type I diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature. 2007;450:887-892.
58.
Barroso I.Genetics of type 2 diabetes. Diabet Med. 2005 ;22:517-535.
59.
Wolford JK, Vozarova de Courten B. Genetic basis of type 2 diabetes mellitus: implications for therapy . Treat Endocrinol. 2004;2:257-267.
